RepliCel Life Sciences Inc. (RP.V) Research

Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a regenerative medicine company dedicated to developing innovative autologous cell therapies. These treatments are designed to correct functional cellular deficiencies by harnessing a patient's own cells. The process involves isolating cells from harvested tissues, significantly expanding them in a controlled laboratory environment, and subsequently applying them therapeutically. The company's developmental portfolio includes several key product candidates: RCT-01 targets chronic tendinosis, RCS-01 addresses aging and sun-damaged skin, and RCH-01 is aimed at treating hair loss. Additionally, RepliCel is advancing RCI-02, a specialized dermal injection device. RepliCel has established significant strategic alliances. It holds a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. to establish a clinical research program and facilitate the commercialization of RCS-01 and RCT-01. A similar collaboration exists with Shiseido Company, Limited, focusing on the clinical research program for RCH-01. Furthermore, the company is engaged in a research project agreement with the University of British Columbia, contributing to the creation of a comprehensive hair follicle cell data map.

Market snapshot

Symbol
RP.V
Price
$0.02
Day change
+50.00%
Market cap
$1.1M
P/E ratio
-9.60x
52-week range
0.01-0.065
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Braxia Scientific Corp. (BRAX.CN)
  • BC Craft Supply Co. Ltd. (CRFT.CN)
  • HAVN Life Sciences Inc. (HAVN.CN)
  • Enlighta Inc. (NLTA.V)
  • PsyBio Therapeutics Corp. (PSYB.V)
  • Pure Extracts Technologies Corp. (PULL.CN)
  • SLANG Worldwide Inc. (SLNG.CN)
  • Solarvest BioEnergy Inc. (SVS.V)

Open RepliCel Life Sciences Inc. (RP.V) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.